Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INDV Stock Forecast 2026-2027
$32.70
Current Price
$4.09B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INDV Price Targets
+65.1%
To High Target of $54.00
+46.8%
To Median Target of $48.00
+19.3%
To Low Target of $39.00
INDV Price Momentum
+3.5%
1 Week Change
+11.6%
1 Month Change
+262.9%
1 Year Change
-8.9%
Year-to-Date Change
-13.9%
From 52W High of $38.00
+276.3%
From 52W Low of $8.69
📊 TOP ANALYST CALLS
Did INDV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Indivior is one of their latest high-conviction picks.
Latest INDV Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, INDV has a bullish consensus with a median price target of $48.00 (ranging from $39.00 to $54.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $32.70, the median forecast implies a 46.8% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INDV Analyst Ratings
7
Buy
0
Hold
0
Sell
INDV Price Target Range
Low
$39.00
Average
$48.00
High
$54.00
Current: $32.70
Latest INDV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INDV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 12, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $48.00 |
| Oct 31, 2025 | Piper Sandler | David Amsellem | Overweight | Reiterates | $41.00 |
| Oct 30, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $35.00 |
| Aug 27, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $34.00 |
| Aug 6, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Initiates | $28.00 |
| Jul 22, 2025 | Jefferies | Dennis Ding | Buy | Assumes | $20.00 |
| Jun 30, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $22.00 |
| Mar 6, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $13.00 |
| Oct 25, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $16.00 |
| Oct 11, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $15.00 |
| Oct 11, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $16.00 |
| Sep 13, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $22.00 |
| Jul 23, 2024 | Piper Sandler | David Amsellem | Overweight | Initiates | $22.00 |
| Jul 10, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $24.00 |
| Apr 3, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $37.00 |
Indivior Pharmaceuticals, Inc. (INDV) Competitors
The following stocks are similar to Indivior based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Indivior Pharmaceuticals, Inc. (INDV) Financial Data
Indivior Pharmaceuticals, Inc. has a market capitalization of $4.09B with a P/E ratio of 19.9x. The company generates $1.24B in trailing twelve-month revenue with a 16.9% profit margin.
Revenue growth is +19.7% quarter-over-quarter, while maintaining an operating margin of +37.2% and return on equity of -212.1%.
Valuation Metrics
Market Cap
$4.09B
Enterprise Value
$4.25B
P/E Ratio
19.9x
PEG Ratio
0.0x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
+19.7%
Gross Margin
+81.3%
Operating Margin
+37.2%
Net Margin
+16.9%
EPS Growth
+385.7%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
0.7x
Debt/Equity
-3.5x
ROE
-212.1%
ROA
+19.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Indivior Pharmaceuticals, Inc. (INDV) Business Model
About Indivior Pharmaceuticals, Inc.
What They Do
Specialty pharmaceutical company for opioid addiction treatments.
Business Model
The company develops and commercializes buprenorphine-based medications, primarily generating revenue through the sale of its core products, SUBLOCADE and SUBOXONE Film. These products cater to patients dealing with opioid use disorder, addressing a significant market need.
Additional Information
Indivior operates in key markets such as the U.S., Europe, Canada, and Australia, with a strong focus on the U.S. market where the demand for addiction therapies is high. The company was founded in 2014 and is headquartered in North Chesterfield, Virginia, contributing to the global fight against the opioid crisis through innovative treatment options.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
827
CEO
Mr. Joseph J. Ciaffoni
Country
United States
IPO Year
2014
Website
www.indivior.comIndivior Pharmaceuticals, Inc. (INDV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Theravance Stock Declines Around 17% in Three Months: Here's Why
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
Apr 16, 2026
By Zacks Equity Research
Analyst Blog
CGON Stock Up 60.8% in Six Months: Here's What You Need to Know
CG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence.
Apr 15, 2026
By Zacks Equity Research
Analyst Blog
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.
Apr 14, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Indivior PLC announced a survey indicating correctional leaders see staffing gaps as barriers to medication diversion for opioid use disorder. Long-acting injectable buprenorphine is viewed as a potential solution.
Why It Matters
Indivior's focus on LAI buprenorphine in correctional facilities could enhance its market position and revenue potential, signaling growth opportunities in the opioid treatment sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Indivior Pharmaceuticals will report Q1 2026 financial results on April 30, 2026, at 7:00 a.m. EDT, followed by a webcast presentation at 8:00 a.m. EDT.
Why It Matters
Indivior's upcoming financial results and leadership presentation could influence stock performance, investor sentiment, and market expectations regarding the company's growth and strategy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99%
9 days ago
Quick Summary
Indivior Pharmaceuticals Inc. (INDV) has a consensus price target indicating a 46% upside potential, supported by an upward trend in earnings estimate revisions.
Why It Matters
The 46% upside potential signals strong growth expectations for Indivior Pharmaceuticals, while positive earnings revisions suggest a favorable short-term outlook, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The Zacks Medical-Drugs industry is experiencing significant innovation. Stocks INDV, CPRX, TBPH, RLMD, and AVTX may be promising portfolio additions.
Why It Matters
The peak of innovation in the Zacks Medical-Drugs industry signals growth potential, making INDV, CPRX, TBPH, RLMD, and AVTX attractive investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Indivior's stock has surged 300% since 2024 lows, supported by stable Sublocade market share, cost controls, and shareholder activism. It targets 8% sales growth and has a $400M buyback planned.
Why It Matters
Indivior's strong performance and growth targets signal potential for continued gains, while a stock buyback enhances shareholder value, making it an appealing investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Indivior Pharmaceuticals' SUBLOCADE® may lower staff time and costs in jails and prisons for opioid use disorder treatment, per a model published in The Journal of Current Medical Research and Opinion.
Why It Matters
Cost savings and efficiency improvements from SUBLOCADE® in correctional facilities could enhance Indivior's market position, potentially boosting revenues and investor confidence in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About INDV Stock
What is Indivior Pharmaceuticals, Inc.'s (INDV) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Indivior Pharmaceuticals, Inc. (INDV) has a median price target of $48.00. The highest price target is $54.00 and the lowest is $39.00.
Is INDV stock a good investment in 2026?
According to current analyst ratings, INDV has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $32.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INDV stock?
Wall Street analysts predict INDV stock could reach $48.00 in the next 12 months. This represents a 46.8% increase from the current price of $32.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Indivior Pharmaceuticals, Inc.'s business model?
The company develops and commercializes buprenorphine-based medications, primarily generating revenue through the sale of its core products, SUBLOCADE and SUBOXONE Film. These products cater to patients dealing with opioid use disorder, addressing a significant market need.
What is the highest forecasted price for INDV Indivior Pharmaceuticals, Inc.?
The highest price target for INDV is $54.00 from at , which represents a 65.1% increase from the current price of $32.70.
What is the lowest forecasted price for INDV Indivior Pharmaceuticals, Inc.?
The lowest price target for INDV is $39.00 from at , which represents a 19.3% increase from the current price of $32.70.
What is the overall INDV consensus from analysts for Indivior Pharmaceuticals, Inc.?
The overall analyst consensus for INDV is bullish. Out of 4 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $48.00.
How accurate are INDV stock price projections?
Stock price projections, including those for Indivior Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:08 AM UTC